title: [The prognosis of bilateral breast carcinoma compared to unilateral breast tumor. 5- and 10-year follow-ups].
abstract: OBJECTIVE
  A review of published data does not provide a certainty whether survival rates are comparable or worse in women with bilateral breast cancer versus patients with an unilateral tumor. Therefore results of therapy in one-sided and both-sided breast cancer were retrospectively analysed.
  
  
  METHODS
  In a period from 1977 to 1982 (follow-up 5 to 12 years) 531 breast cancer patients with T1-4 N0-3 M0 tumors were treated with mastectomy (n = 416) and breast conserving therapy (n = 115). Postoperative radiotherapy was performed in all patients (50 Gy, 2 Gy/day 5 times/weekly; chest wall/breast and regional lymph nodes). Patients with positive lymph nodes received chemotherapy. Forty patients developed bilateral breast cancer (simultaneous n = 10, metachronous n = 30) that was treated by mastectomy (n = 28) and conservative surgery (n = 12), respectively, followed by radiotherapy in 26 women.
  
  
  RESULTS
  Five- and 10-year survival was 74% and 56% in unilateral affected women. In 83% and 67% there were no metastases, respectively. Incidence of metastases was 27.9%. In bilateral breast cancer group survival rates were 85% and 59% and without evidence of metastases 87% and 60%, respectively. Distant disease was diagnosed in 35%. Differences between the 2 groups were statistically not significant. Whereas in time of follow-up 11% of unilateral cancer locally failed in bilateral cancer patients recurrences of the first and second tumor were seen in 20% and 10%, respectively.
  
  
  CONCLUSIONS
  Survival of patients with bilateral breast cancer is not significantly decreased compared with unilateral disease although in patients with both-sided carcinoma local recurrences and metastases seem to occur more frequently.
authors.affiliation: Abteilung für Strahlentherapie und Onkologie, Johann-Wolfgang-Goethe-Universität, Frankfurt am Main.
authors.forename: S
authors.initials: S
authors.lastname: Mose
authors.forename: I A
authors.initials: IA
authors.lastname: Adamietz
authors.forename: C
authors.initials: C
authors.lastname: Thilmann
authors.forename: F
authors.initials: F
authors.lastname: Saran
authors.forename: R
authors.initials: R
authors.lastname: Pahnke
authors.forename: H D
authors.initials: HD
authors.lastname: Böttcher
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001943:Breast Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D002277:Carcinoma / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008207:Lymphatic Metastasis; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D016609:Neoplasms, Second Primary / Q000401:mortality* / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D012189:Retrospective Studies; D013997:Time Factors
vernacular_title: Die Prognose des bilateralen Mammakarzinoms im Vergleich zum unilateralen Mammatumor. Follow-up nach fünf und zehn Jahren.